Akero Therapeutics

Ask Sterling

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving the EV sector growth?

Favorites

Revenue Breakdown

Revenue Flow

Balance Sheet

Q4 2017-Q3 2025(All available data)

Cash Flow

Q4 2017-Q3 2025(All available data)

Akero Therapeutics

Efruxifermin (FGF21 analog) for MASH. Novo Nordisk agreed to acquire Akero for $5.2B in late 2025, positioning MASH as combinable with GLP-1.

$AKROSouth San Francisco, CA80akerotx.com

SectorsGLP-1

Frequently asked questions

What does Akero Therapeutics do?

Akero Therapeutics (AKRO) is a Biotechnology company. Efruxifermin (FGF21 analog) for MASH. Novo Nordisk agreed to acquire Akero for $5.2B in late 2025, positioning MASH as combinable with GLP-1. It was founded in 2017, is headquartered in South San Francisco, CA and employs about 80 people.

How has Akero Therapeutics's revenue and profitability trended?

Track Akero Therapeutics's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 21, 2026.

Who are Akero Therapeutics's main competitors?

Sterling groups Akero Therapeutics in the GLP-1 sector, alongside Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE), Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).

If I'm investing in Akero Therapeutics, what similar companies should I consider?

If you are researching Akero Therapeutics, also look at Eli Lilly (LLY), Novo Nordisk (NVO) and Pfizer (PFE). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.